Wegovy supply constraints only affect the USA market

Due to high demand, the giant manufacturer Novo Nordisk has temporarily cut the wegovy supply for the starter doses of its popular weight-loss drug Wegovy by 50% due to wegovy supply constraints

Novo Nordisk is a Danish multinational pharmaceutical giant company that specializes in the production and distribution of diabetes care products, as well as other chronic disease treatments like obesity. The company has a global presence and is one of the world’s leading producers of insulin and weight loss drug,wegovy The company is the major drug supplier in the United States.This giant pharmaceutical company is facing wegovy supply constraints for May and this may last for few months as announced by the copmpany recently .The popularity of Novo Nordisk’s weight loss drugs, including Wegovy, has surged in the United States due in part to the influence of social media trends. People have been increasingly talking about and sharing their experiences with these drugs on platforms such as Instagram and TikTok, leading to a higher demand for them.Novo Nordisk a Danish company, headquartered in Bagsvaerd, has announced that it will temporarily reduce the supply of starter doses of its popular weight-loss drug, Wegovy, in the United States to cope with high demand globally.

The company has faced supply constraints for Wegovy, which has seen overwhelming demand since its launch in the US in June 2021. Sales of Novo’s obesity care products, including Wegovy, rose by 124% in the first quarter, and the company has invested heavily in increasing supply. To safeguard continuity of care for those patients who have started treatment, the supply of the lower Wegovy dose strengths in the US will be reduced by around 50% for “some months.” Novo Nordisk has said that a second contract manufacturer has commenced production of Wegovy, and a third manufacturer will begin production later this year.Novo Nordisk CEO Lars Fruergaard Jorgensen stated that the supply of starter doses in the U.S. would be cut by around 50% for “some months.”

Other weight loss trending medication

Tirzepatide

The FDA has approved Mounjaro (tirzepatide) injection for improving blood sugar control in adults with type 2 diabetes as an adjunct to diet and exercise. In addition, Mounjaro has received Fast Track designation from the FDA for the treatment of adults who are overweight or obese and have weight-related comorbidities. Obesity is a chronic condition that affects a large population of Americans and is associated with various severe health issues, such as stroke, heart disease, diabetes, and some types of cancer. Although existing obesity treatments exist, they may not be effective for some patients, and diet and exercise alone may not achieve desired treatment goals.

Semaglutide (Ozempic)

While not approved by the FDA for weight loss, Ozempic is still a popular medication used off-label for weight management, belonging to the same class of drugs as Wegovy called GLP-1 agonists. It’s worth mentioning that using medications off-label should only be done with the guidance of a healthcare professional, and patients should always follow their doctor’s instructions and recommendations.

Note :The Wegovy is available in five different strengths: 0.25 mg, 0.5 mg, 1 mg, and 1.7 mg.2.4 milligrams